Skip to main
  1. Stocks
  2. Pyxis Oncology
  3. Forecast
PYXS

Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology (PYXS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pyxis Oncology is supported by MICVO’s encouraging monotherapy profile in 2L+ R/M HNSCC, where 33 efficacy-evaluable patients produced a 36% cORR, 94% DCR, 6.2-month mPFS, and 12-month OS probability of 79%, while discontinuations fell to 14.3% after the dose cap, improving the tolerability case. The company also has multiple near-term catalysts, including updated 1L pembrolizumab-combination data in 4Q26, FDA dose-selection feedback in 1Q27, and updated OS data in 1H27, all of which could further de-risk the pivotal HEADLINER program planned for mid-2027. Financially, it reported a $20.0M net loss in 3Q26, ended with $57.0M in cash, and added about $110.0M from an October 1 offering, extending runway into 1H28 and strengthening execution flexibility.

Bears say

Pyxis Oncology is a small biotech with no revenues, leaving it heavily dependent on MICVO’s clinical success and external financing to fund ongoing R&D. The bearish view rests on the possibility of unacceptable toxicity, weaker-than-needed efficacy, an unfavorable therapeutic window, or regulatory setbacks such as clinical holds, any of which could halt development. Even with recent safety improvements, MICVO still must clear a pivotal trial in a highly competitive oncology market, and failure to do so could leave shares trading near cash, estimated at about $0.50 within 12 months.

Pyxis Oncology (PYXS) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.

Pyxis Oncology (PYXS) Analyst Forecast & Price Prediction

Get the latest Pyxis Oncology (PYXS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pyxis Oncology (PYXS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pyxis Oncology (PYXS) Forecast

Analysts have given Pyxis Oncology (PYXS) a Buy based on their latest research and market trends.

According to 7 analysts, Pyxis Oncology (PYXS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pyxis Oncology (PYXS)


Pyxis Oncology (PYXS) Analyst Forecast & Price Prediction

Get the latest Pyxis Oncology (PYXS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pyxis Oncology (PYXS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PYXS stock data and trends